. Author manuscript; available in PMC: 2021 May 25.

Published in final edited form as: Curr Hematol Malig Rep. 2017 Oct;12(5):381–388. doi: 10.1007/s11899-017-0399-5

Table 2.

MPN PRO use in clinical trials by therapy

	Trial Name	MPN	PRO
Ruxolitinib	COMFORT 1	Myelofibrosis	MF-SAF 2.0
	COMFORT 2	Myelofibrosis	FACT-LYM
	RETHINK	Myelofibrosis	MPN-10
	RESPONSE	Polycythemia vera	MPN-SAF
	RELIEF	Polycythemia vera	MPN-SAF
	MAGIC	Essential thrombocythemia	MPN-SAF
Fedratinib	JAKARTA	Myelofibrosis	MF-SAF
Pacritinib	PERSIST 1&2	Myelofibrosis	MPN-SAF
Momelotinib	SIMPLIFY 1&2	Myelofibrosis	MPN-SAF
Pomalidomide	RESUME	Myelofibrosis	FACT-AN
PEG INFa2a	MPD-RC112	Myelofibrosis	MPN-SAF
	MPD-RC112	Essential thrombocythemia	MPN-SAF

FACT-LYM Functional Assessment of Cancer Therapy in Lymphoma, MF-SAF Myelofibrosis Symptom Assessment Form, MPN-SAF Myeloproliferative Neoplasm Symptom Assessment Form, PEG INFa2a pegylated-interferon alpha-2a